Over-expression of α-synuclein 98 triggers intracellular oxidative stress and enhances susceptibility to rotenone

Neuroscience Letters

Volumn 491, Issue 2, 2011, Pages 148-152

  Ma, Kai Li ^a   Yuan, Yu He ^a   Song, Lian Kun ^a   Han, Ning ^a   Chen, Nai Hong ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Synuclein; Malondialdehyde; Oxidative stress; Parkinson's disease; Reactive oxygen species; Rotenone

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; ALPHA SYNUCLEIN; FREE RADICAL; REACTIVE OXYGEN METABOLITE; ROTENONE;

ARTICLE; BRAIN; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CYTOPLASM; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; HUMAN; INTRACELLULAR SIGNALING; LEWY BODY; LIPID PEROXIDATION; NERVE CELL; NEUROTOXICITY; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; START CODON; STEADY STATE; WILD TYPE;

ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; HUMANS; MALONDIALDEHYDE; NEURONS; OXIDATIVE STRESS; PROTEIN ISOFORMS; RATS; REACTIVE OXYGEN SPECIES; ROTENONE; UNCOUPLING AGENTS;

EID: 79951580097     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.01.026     Document Type: Article

References (40)

1. Ahmadi F.A., Linseman D.A., Grammatopoulos T.N., Jones S.M., Bouchard R.J., Freed C.R., Heidenreich K.A., Zawada W.M. The pesticide rotenone induces caspase-3-mediated apoptosis in ventral mesencephalic dopaminergic neurons. J. Neurochem. 2003, 87:914-921.
2. Albani D., Peverelli E., Rametta R., Batelli S., Veschini L., Negro A., Forloni G. Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70. FASEB J. 2004, 18:1713-1715.
3. Baba M., Nakajo S., Tu P.H., Tomita T., Nakaya K., Lee V.M., Trojanowski J.Q., Iwatsubo T. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 1998, 152:879-884.
4. Beyer K., Domingo-Sabat M., Lao J.I., Carrato C., Ferrer I., Ariza A. Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases. Neurogenetics 2008, 9:15-23.
5. Bodles A.M., Guthrie D.J., Greer B., Irvine G.B. Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 2001, 78:384-395.
6. Bodles A.M., Guthrie D.J., Harriott P., Campbell P., Irvine G.B. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem. 2000, 267:2186-2194.
7. Bossy-Wetzel E., Schwarzenbacher R., Lipton S.A. Molecular pathways to neurodegeneration. Nat. Med. 2004, 10(Suppl.):S2-S9.
8. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
9. el-Agnaf O.M., Irvine G.B. Aggregation and neurotoxicity of alpha-synuclein and related peptides. Biochem. Soc. Trans. 2002, 30:559-565.
10. Forman M.S., Lee V.M., Trojanowski J.Q. Nosology of Parkinson's disease: looking for the way out of a quagmire. Neuron 2005, 47:479-482.
11. Giasson B.I., Duda J.E., Murray I.V., Chen Q., Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000, 290:985-989.
12. Giasson B.I., Murray I.V., Trojanowski J.Q., Lee V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276:2380-2386.
13. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
14. Goers J., Manning-Bog A.B., McCormack A.L., Millett I.S., Doniach S., Di Monte D.A., Uversky V.N., Fink A.L. Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry 2003, 42:8465-8471.
15. Goldberg M.S., Lansbury P.T. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?. Nat. Cell Biol. 2000, 2:E115-E119.
16. Greenamyre J.T., Betarbet R., Sherer T.B. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat. Disord. 2003, 9(Suppl. 2):S59-64.
17. Greenamyre J.T., MacKenzie G., Peng T.I., Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 1999, 66:85-97.
18. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999, 10:717-721.
19. Hashimoto M., Takeda A., Hsu L.J., Takenouchi T., Masliah E. Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease. J. Biol. Chem. 1999, 274:28849-28852.
20. Hoglinger G.U., Oertel W.H., Hirsch E.C. The rotenone model of parkinsonism-the five years inspection. J. Neural Transm. 2006, (Suppl.):269-272.
21. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 1998, 13(Suppl. 1):24-34.
22. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 2002, 320:146-150.
23. Kitamura Y., Inden M., Miyamura A., Kakimura J., Taniguchi T., Shimohama S. Possible involvement of both mitochondria- and endoplasmic reticulum-dependent caspase pathways in rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurosci. Lett. 2002, 333:25-28.
24. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000, 11:211-213.
25. Lashuel H.A., Hartley D., Petre B.M., Walz T., Lansbury P.T. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418:291.
26. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2162-2167.
27. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
28. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988, 8:2804-2815.
29. Moon Y., Lee K.H., Park J.H., Geum D., Kim K. Mitochondrial membrane depolarization and the selective death of dopaminergic neurons by rotenone: protective effect of coenzyme Q10. J. Neurochem. 2005, 93:1199-1208.
30. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008, 65:1272-1284.
31. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
32. Radad K., Rausch W.D., Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. Neurochem. Int. 2006, 49:379-386.
33. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54:823-827.
34. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
35. Souza J.M., Giasson B.I., Chen Q., Lee V.M., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 2000, 275:18344-18349.
36. Specht C.G., Tigaret C.M., Rast G.F., Thalhammer A., Rudhard Y., Schoepfer R. Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol. Cell. Neurosci. 2005, 28:326-334.
37. Turnbull S., Tabner B.J., El-Agnaf O.M., Moore S., Davies Y., Allsop D. alpha-Synuclein implicated in Parkinson's disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med. 2001, 30:1163-1170.
38. von Bohlen Und Halbach O. Synucleins and their relationship to Parkinson's disease. Cell Tissue Res. 2004, 318:163-174.
39. Xia Y., Saitoh T., Ueda K., Tanaka S., Chen X., Hashimoto M., Hsu L., Conrad C., Sundsmo M., Yoshimoto M., Thal L., Katzman R., Masliah E. Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms. J. Alzheimers Dis. 2001, 3:485-494.
40. Yuan Y., Jin J., Yang B., Zhang W., Hu J., Zhang Y., Chen N.H. Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway. Cell. Mol. Neurobiol. 2008, 28:21-33.